BALTIMORE, MD
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE LIEBER INSTITUTE INC, founded in 2008, is a mid-sized nonprofit in the Medical Research sector that reported $28.9M in total revenue in fiscal year 2022. Revenue surged 26% from the prior year, signaling strong growth momentum.
THE MISSION OF THE INSTITUTE IS TO TRANSLATE BASIC GENETIC AND MOLECULAR MECHANISMS OF SCHIZOPHRENIA AND RELATED DEVELOPMENTAL BRAIN DISORDERS INTO CLINICAL ADVANCES THAT CHANGE THE LIVES OF AFFECTED INDIVIDUALS. IT IS CATALYZING A NEW UNDERSTANDING OF BRAIN DISEASE BY LINKING ADVANCES IN THE CONSTRUCTION AND FUNCTION OF THE HUMAN BRAIN WITH THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES.
CLINICAL SCIENCES: THE CLINICAL SCIENCE DIVISION INVESTIGATES MECHANISMS OF SCHIZOPHRENIA AND RELATED BRAIN DISORDERS IN CLINICAL STUDIES AND IN BIOLOGICAL MATERIAL FROM CLINICAL SAMPLES SPECIFICALLY...
CLINICAL SCIENCES: THE CLINICAL SCIENCE DIVISION INVESTIGATES MECHANISMS OF SCHIZOPHRENIA AND RELATED BRAIN DISORDERS IN CLINICAL STUDIES AND IN BIOLOGICAL MATERIAL FROM CLINICAL SAMPLES SPECIFICALLY ASCERTAINED, EVALUATED AND MANAGED BY INSTITUTE STAFF AND THROUGH COLLABORATIONS WITH JOHNS HOPKINS UNIVERSITY, THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), UNIVERSITY OF BARI (ITALY), MEDICAL COLLEGE OF VIRGINIA, MORGAN STATE UNIVERSITY AND OTHERS.
BASIC SCIENCES: THE CREATION OF MODEL SYSTEMS AT THE INSTITUTE TO STUDY PSYCHIATRIC ILLNESS IS THE MAJOR GOAL OF THE BASIC SCIENCES RESEARCH PROGRAM. USING OUR UNIQUE COLLECTION OF HUMAN BRAIN...
BASIC SCIENCES: THE CREATION OF MODEL SYSTEMS AT THE INSTITUTE TO STUDY PSYCHIATRIC ILLNESS IS THE MAJOR GOAL OF THE BASIC SCIENCES RESEARCH PROGRAM. USING OUR UNIQUE COLLECTION OF HUMAN BRAIN MATERIAL AND INDUCED PLURIPOTENT STEM CELL LINES, WE ARE DEFINING THE MOLECULAR SIGNATURE OF DISEASE RISK. TO PROVIDE THE BASIS FOR THERAPEUTIC INTERVENTION WE ARE DEVELOPING NEW TECHNOLOGIES USING HUMAN STEM CELLS TO IDENTIFY THE FUNCTIONAL CONSEQUENCES OF GENETIC RISK FACTORS. THE GOAL OF THESE STUDIES IS THE IDENTIFICATION OF THERAPEUTIC TARGETS BASED ON THE MECHANISMS OF DISEASE.
DRUG DISCOVERY: IMPROVED GENETIC UNDERSTANDING OF DISEASES OF BRAIN DEVELOPMENT IS REVEALING NEW DRUG DISCOVERY OPPORTUNITIES. GUIDED BY GENETICS, THE INSTITUTE'S DRUG DISCOVERY DIVISION IS...
DRUG DISCOVERY: IMPROVED GENETIC UNDERSTANDING OF DISEASES OF BRAIN DEVELOPMENT IS REVEALING NEW DRUG DISCOVERY OPPORTUNITIES. GUIDED BY GENETICS, THE INSTITUTE'S DRUG DISCOVERY DIVISION IS INVESTIGATING NEW TARGETS FOR PSYCHIATRIC DISEASES, WITH THE GOAL OF VALIDATING INNOVATIVE APPROACHES THAT WILL LEAD TO NOVEL MEDICINES FOR PATIENTS SUFFERING FROM THESE CONDITIONS. THE DRUG DISCOVERY DIVISION MAINTAINS A STATE OF THE ART MEDICINAL CHEMISTRY LABORATORY AND UNIQUE CAPABILITIES IN TARGET VALIDATION.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2022 | 2021 | Change | |
|---|---|---|---|
| Revenue | $28,903,115 | $22,894,222 | +0.3% |
| Expenses | $31,448,930 | $29,512,998 | +0.1% |
| Net Income | $-2,545,815 | $-6,618,776 | -0.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| HERBERT PARDES MD | CHAIRMAN OF THE BOARD | 1.00 |
Director
|
$0 | $0 | $0 |
| STEVEN S SHARFSTEIN MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| PAUL B ROTHMAN MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| GEOFFREY SIMON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MARY RUBIN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TAMAR MALTZ | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MILTON MALTZ | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT MUSE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DANIEL R GETTS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LANDON S KING | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DANIEL R WEINBERGER | CEO & DIRECTOR | 40.00 |
Officer
Director
|
$763,001 | $26,761 | $789,762 |
| THOMAS MICHAEL HYDE | CHIEF MEDICAL OFFICER | 40.00 |
Officer
|
$411,393 | $26,761 | $438,154 |
| ELAINE JONES | CHIEF OPERATING OFFICER | 40.00 |
Officer
|
$414,835 | $10,250 | $425,085 |
| ANDREW MASLAN | CFO & TREASURER | 40.00 |
Officer
|
$347,452 | $32,033 | $379,485 |
| JAMES BARROW | ASSOC. DIR. OF DRUG DISCOV | 40.00 |
Key Emp
|
$337,058 | $32,049 | $369,107 |
| JOEL E KLEINMAN | ASSOC. DIR. OF CLINICAL SC | 40.00 |
Highest
|
$397,458 | $26,761 | $424,219 |
| BRADY MAHER | LEAD INVESTIGATOR | 40.00 |
Highest
|
$213,151 | $31,106 | $244,257 |
| SHIZHONG HAN | LEAD INVESTIGATOR, DATA SC | 40.00 |
Highest
|
$197,004 | $30,931 | $227,935 |
| KERI MARTINOWICH | LEAD INVESTIGATOR | 40.00 |
Highest
|
$203,954 | $31,139 | $235,093 |
| GREGORY CARR | LEAD INVESTIGATOR | 40.00 |
Highest
|
$191,487 | $31,267 | $222,754 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | No data | No data | No data | No data |
| 2023 | $28,903,115 | $31,448,930 | $36,656,603 | $-2,545,815 |
| 2022 | $22,894,222 | $29,512,998 | $31,106,210 | $-6,618,776 |
| 2021 | $35,823,160 | $27,198,424 | $44,686,565 | $8,624,736 |
| 2020 | $17,247,195 | $28,499,790 | $32,856,647 | $-11,252,595 |
| 2019 | $21,791,141 | $26,379,595 | $44,500,781 | $-4,588,454 |
| 2018 | $20,649,548 | $26,899,975 | $52,981,874 | $-6,250,427 |
Compare THE LIEBER INSTITUTE INC with other nonprofits in Maryland and across the country.